Seagen and genmab announce u.s. fda filing acceptance for priority review of tisotumab vedotin biologics license application for patients with recurrent or metastatic cervical cancer

Bothell, wash. & copenhagen, denmark--(business wire)--seagen inc. (nasdaq: sgen) and genmab a/s (nasdaq: gmab) today announced that the u.s. food and drug administration (fda) has accepted for priority review the biologics license application (bla) seeking accelerated approval for tisotumab vedotin. this bla requests fda approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. under the prescript
SGEN Ratings Summary
SGEN Quant Ranking